Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
The arrival of targeted therapeutics into the oncology clinic, while enthusiastically anticipated, introduced the oncologist to dermatologic events that can pose challenging management issues. The dermatologic effects of these targeted agents appear to be more frequent than those with cytotoxic therapy and are not uniform; that is, different agents have distinct dermatologic toxicities. Interestingly, dermatologic toxicity may correlate with antitumor activity with some of these targeted agents. The correlation of rash with response and survival in particular mandates the development of effective and appropriate management strategies. The nature and challenges of the dermatologic events observed to date with epidermal growth factor receptor inhibitors, multikinase inhibitors, proteosome inhibitors, BCR-ABL tyrosine kinase inhibitors, and immunomodulatory drugs will be addressed in this review.
Hammond-Thelin
Lisa A
LA
6126 Amble Trail, San Antonio, TX 78249, USA. lisa.hammond-md@satx.rr.com
D000970:Antineoplastic Agents / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D012017:Referral and Consultation; D012871:Skin Diseases / Q000139:chemically induced* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors